Last reviewed 2026-04-20 · How we verify

Chrft5 (BASILIXIMAB)

At a glance

Approved indications

• Renal transplant rejection

Boxed warnings

• WARNING Only physicians experienced in immunosuppression therapy and management of organ transplantation patients should prescribe Simulect ® (basiliximab). The physician responsible for Simulect administration should have complete information requisite for the follow-up of the patient. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources.

Common side effects

• Gastrointestinal disorder
• Gastroenteritis
• GI hemorrhage
• Gum hyperplasia
• Hypertriglyceridemia
• Hypocalcemia
• Hypoglycemia
• Hypomagnesemia
• Hypoproteinemia
• Leucopenia
• Malaise
• Melena

Key clinical trials

• Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
• Valganciclovir Prophylaxis Versus Preemptive Therapy for Cytomegalovirus in Living Donor Kidney Transplant Recipients (PHASE4)
• Examination of Immunosuppression Adjustment Impact on Kidney Function in Liver Transplant (PHASE4)
• Simulect Versus ATG in Sensitized Renal Transplant Patient (PHASE4)
• Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma (PHASE2)
• A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients (PHASE2)
• Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR (PHASE4)
• Stem Cell Transplantation for Patients With Multiple Myeloma (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.